Loyal's Preventive Senior Care Play

The opening for Loyal is not just a new drug, it is a different buying moment. Zoetis, Elanco, and Boehringer mostly sell into moments when a dog already has a clear problem, like parasites, itch, pain, heart failure, or osteoarthritis. Loyal is trying to create a routine senior care category where vets prescribe before major disease shows up, which turns aging itself into the reason for an ongoing prescription.

• The incumbent portfolios show where industry attention has gone. Zoetis highlights parasiticides, dermatology, and osteoarthritis pain. Elanco emphasizes parasiticides, dermatology, vaccines, and pain. Boehringer markets parasite control, pain drugs like Metacam, and heart failure drugs like Vetmedin. These are large treatment categories tied to identifiable conditions.
  2 zoetis 3 zoetis 4 elanco 5 elanco 6 boehringeringelheim
• Loyal is building a prevention style workflow that fits normal vet behavior. LOY-002 is a daily pill for dogs 10 and older, LOY-001 is a periodic injection for large breeds, and all three programs are meant to slot into routine checkups and refills. That makes the product feel closer to chronic maintenance than acute rescue care.
  1 sacra 7 loyal
• The strategic prize is bigger than one pill. If vets begin screening older dogs for metabolic decline and prescribing longevity drugs earlier, Loyal can add diagnostics, biomarker panels, and follow on aging indications like cognition, joints, and immune support. That would move spend upstream, before a dog becomes visibly sick.
  7 loyal

If Loyal proves this category, the incumbents have the scale to respond quickly, but they would be following a market definition that Loyal helped create. The next phase of competition will be about owning senior pet maintenance, not just treating the diseases that appear at the end of a dog's life.